EARTH study – first patient enrolled in Mali

We are delighted to report that the Centre Hospitalier Universitaire Gabriel Touré in Mali (in liaison with Anne-Genevieve Marcelin, France) has enrolled its first patient in the key EPIICAL study, EARTH. This marks a new chapter in the study, with the scope of the cohort widening to include participants not only from South Africa and Mozambique, but also from the west African site in Bamako. Continue reading “EARTH study – first patient enrolled in Mali”

EPIICAL at IAS 2019

With issue of the 2nd EPIICAL newsletter, we are pleased to announce that a poster on the CARMA study has been accepted for a presentation at both the 10th International AIDS Society 2019 Conference on HIV Science and pre-meeting ‘2019 HIV & HBV Cure Forum‘.

Pablo Rojo, on behalf of the CARMA study researchers, will illustrate the main factors associated with low viral reservoir in a large multi-centre cohort of early treated children infected with HIV on sustained suppressive ART for more than a decade. Globally, the CARMA study is the focal point of EPIICAL investigations and will provide important insights into clinical and biological features of early treated suppressed HIV-infected children, as well as novel strategies to achieve long-term viral suppression without ART in this particular population.

The biannual IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. Gathering more than 5,000 participants from over 140 countries, IAS 2019 will present the most critical advances in basic, clinical and operational HIV research that moves science into policy and practice.

Read more here!

1st EPIICAL Newsletter

With the EPIICAL project being a hive of activity over the last year, we have collected a selection of contributions, stories and articles to bring you the very first edition of the EPIICAL newsletter! The issue contains an update on the evolution and recent progress in the HIV pediatric research coordinated by the project. We get to know the clinicians that locally sustain HIV programs and services with reports of their experience in the EARTH (‘Early Anti-Retroviral Treatment in HIV-infected Children’) study. Moreover, we take a closer look at a team of young researchers in their day-to-day work. We extend our thanks to all involved who contributed with their views, knowledge and personal skills to highlight the spirit and mission of the EPIICAL consortium.

Read more here!

CROI 2019: Oral presentation by members of the EPIICAL team

The annual Conference on Retroviruses and Opportunistic Infections (CROI) was held on 4-7 March 2019, at the Washington State Convention Center in Seattle, Washington. CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

At this year’s event, EPIICAL team member Sara Dominguez Rodriguez delivered the following oral presentation:

NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION

Alfredo Tagarro, Sara Dominguez Rodriguez, Thanyawee Puthanakit, Paolo Palma, Caroline Foster, Thidarat Jupimai, Nicola Cotugno, Jintanat Ananworanich, Santiago Jimenez de Ory, Paola Zangari, Maria Luisa Navarro, Paolo Rossi, Eleni Nastouli, Carlo Giaquinto, Pablo Rojo Conejo

This important study illustrated recent results that provide further evidence that supports the earliest antiretroviral therapy initiation in infants. Early antiretroviral therapy (ART) in children is associated with better clinical and virological outcome. The hypothesis explored is that HIV-perinatally infected neonates initiating ART within <7 days of life have a better long-term clinical and virological response than neonates treated ≥7 days and ≤28 days of life.

You can find the full webcast of the presentation here.

CROI: Members of the EPIICAL team to attend in Seattle

Seattle is gearing up for the 2019 edition of CROI next week. Held at Washington State Convention Center on 4th-7th March, the Conference on Retroviruses and Opportunistic Infections is an important event in the EPIICAL calendar and an opportunity for many consortium members to discuss the latest developments pertaining to the project. Included on the agenda, our researchers will make an oral presentation illustrating recent results that provide further evidence that supports the earliest ART initiation in infants.

CROI is a global model of collaborative science and the premier international venue for bridging basic and clinical investigation to clinical practice in the field of HIV and related viruses. Established in 1993, the event provides a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. It is the preeminent HIV research meeting in the world and attracts more than 4,000 HIV/AIDS research leaders internationally. The goal of the conference is to provide a forum for researchers to translate their laboratory and clinical findings into tangible progress against the HIV pandemic.